Tofacitinib in Vitiligo: Case Series and Open-Label Studies ± NB-UVB
Key Takeaways Tofacitinib (JAK1/3 inhibitor) has shown facial repigmentation in multiple case series; responses improve with concurrent light (NB-UVB or […]
perifollicular repigmentation
Pimecrolimus 1% vs Placebo for Facial Vitiligo: Randomized Controlled Trial Overview
Key Takeaways For facial vitiligo, pimecrolimus 1% shows superiority over placebo on F-VASI and global assessments in several RCTs/split-face designs.
Tacrolimus 0.1% in Vitiligo: Efficacy by Anatomic Zone in Children and Adults
Key Takeaways Facial/neck lesions show the highest response rates to tacrolimus 0.1%, often with early perifollicular islands of repigmentation. Trunk/extremities
NB-UVB + Tacrolimus vs NB-UVB Alone in Vitiligo: Randomized Controlled Trial
Key Takeaways Adding topical tacrolimus to NB-UVB is associated with higher facial response rates and earlier perifollicular repigmentation in many
Excimer 308 nm for Focal Vitiligo: Face/Neck Outcomes, Parameters, and Safety
Key Takeaways Excimer 308 nm is well suited for localized/focal lesions, particularly on the face and neck, enabling targeted high-fluence delivery